Herantis Pharma Oyj
Research Herantis Pharma Oyj (HRTIS) on Bullrun: market cap EUR 43.73M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHRTIS
- ExchangeHE
- CountryFinland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 43.73M
- Financial periodFY2025
- RevenueEUR 0
- Net income-EUR 6.62M
- Free cash flow-EUR 6.10M
Valuation Snapshot
latest market cap is EUR 43.73M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 6.62M | -EUR 6.10M | n/a | n/a | EUR 751.00K | EUR 24.87K | -EUR 1.69M |
| FY2024 | EUR 0 | -EUR 4.94M | -EUR 6.55M | n/a | n/a | EUR 634.52K | EUR 30.00K | -EUR 243.00K |
| FY2023 | EUR 0 | EUR 279.84K | -EUR 4.64M | n/a | 0.02 | EUR 5.50M | EUR 34.82K | EUR 4.73M |
| FY2022 | EUR 0 | -EUR 9.32M | -EUR 8.94M | n/a | -0.64 | EUR 5.04M | EUR 4.54M | -EUR 60.28K |
| FY2021 | n/a | n/a | n/a | n/a | -2.31 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | EUR 43.73M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Herantis Pharma Oyj
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Herantis Pharma Oyj's market cap?
Herantis Pharma Oyj's market capitalization is EUR 43.73M.
What does Herantis Pharma Oyj do?
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. Herantis Pharma Oyj was incorporated in 2008 and is based in Espoo, Finland.